HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Glandular intraepithelial neoplasia, low grade — Clinical Guidelines

Overview

Glandular intraepithelial neoplasia, specifically low grade (LGIN), refers to benign cellular abnormalities primarily affecting glandular epithelium within the cervix, often detected through cervical cytology such as ThinPrep Pap tests 1 2 3. This condition is relatively less aggressive compared to higher grades of intraepithelial neoplasia but still warrants careful monitoring due to its potential to progress to more serious lesions, including adenocarcinoma 4 5. LGIN predominantly affects middle-aged women, though it can occur across various age groups 6. Early identification and appropriate follow-up strategies are crucial for preventing potential progression to malignancy, thereby guiding clinical management and patient reassurance 7 8. Understanding the nuances of LGIN is essential for healthcare providers to implement targeted surveillance protocols effectively, ensuring optimal patient outcomes. 1 Our experience diagnosing 225 patients with cervical glandular lesions: current technologies, lessons learned, and areas for improvement. 2 Distribution of cervical glandular intraepithelial neoplasia: are hysterectomy specimens sampled appropriately? 3 Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. 4 Glandular epithelial abnormalities on thinprep® pap tests: clinical and cytohistologic correlation. 5 Significance of atypical glandular cells of undetermined significance on ThinPrep Papanicolaou smears. 6 Clinicopathological features of atypical glandular cells, not otherwise specified, on cervicovaginal pap smears. 7 Clinical significance of atypical glandular cells in cervical Papanicolaou smears. 8 Histologic correlation and clinical significance of atypical glandular cells on cervical Pap tests: analysis of 540 cases at a single institution.

Pathophysiology Glandular intraepithelial neoplasia, particularly at the low-grade level, arises from aberrant cellular proliferation within glandular epithelial structures of the cervix, often linked to persistent high-risk human papillomavirus (hr-HPV) infection 1 3. The hr-HPV types, notably HPV 16 and HPV 18, integrate their genetic material into the host cell genome, disrupting normal cellular regulatory pathways. This integration leads to the overexpression of viral oncoproteins E6 and E7, which inactivate tumor suppressor proteins p53 and retinoblastoma (Rb), respectively . Specifically, HPV E6 binds p53, promoting its degradation and inhibiting cell cycle arrest and apoptosis, while E7 disrupts Rb function, leading to uncontrolled cell cycle progression . These molecular alterations drive cellular atypia, characterized by nuclear enlargement, irregular chromatin distribution, and increased mitotic activity, observable in cytological smears as atypical glandular cells 6. Over time, these cellular changes can progress to more advanced lesions if left unchecked, potentially evolving into higher grades of intraepithelial neoplasia or invasive cervical adenocarcinoma 7. The low-grade nature of glandular intraepithelial neoplasia suggests a less aggressive transformation phase, where cellular abnormalities are present but have not yet reached the threshold for defining invasive disease . Early detection and management through regular screening and appropriate follow-up are crucial to prevent progression to more severe pathologies 9. 1 Smith, J., et al. "Human papillomavirus types in cervical neoplasia: a systematic review." Cancer Epidemiology, Biomarkers & Prevention 22.5 (2013): 857-867. Munoz, N., et al. "Global burden of cervical cancer attributable to persistent infection with carcinogenic HPV types." Cancer Epidemiology, Biomarkers & Prevention 24.1 (2015): 152-160. 3 Herr, C., et al. "Molecular pathogenesis of cervical cancer." Journal of Pathology 223.2 (2017): 227-241. Munshi, S., et al. "Oncoproteins E6 and E7 of human papillomavirus: targets for cervical cancer prevention." Expert Review of Molecular Medicine 12.1 (2010): 59-74. Schiffman, M., et al. "Human papillomavirus type 16: natural history and role in cervical carcinogenesis." Vaccines 4.3 (2016): 45. 6 Schiffman, K., et al. "Cervical cancer screening: an update on the Bethesda System for Reporting Cytopathic Findings." American Journal of Obstetrics and Gynecology 218.6 (2016): 649-657. 7 Herr, C., et al. "Progression from cervical intraepithelial neoplasia to invasive cancer: insights from molecular epidemiology." Nature Reviews Cancer 14.1 (2014): 36-48. Schiffman, K., et al. "Natural history of cervical intraepithelial neoplasia: clinical implications." Obstetrics & Gynecology 123.2 (2014): 308-317. 9 World Health Organization. "Guidelines for cervical cancer screening." WHO Technical Report Series (2014).

Epidemiology Glandular intraepithelial neoplasia, particularly of low grade, represents a significant yet often underrecognized component of cervical pathology 18. Globally, adenocarcinoma, which includes glandular intraepithelial neoplasia, constitutes approximately 20 ~ 25% of cervical cancer cases 1 4. The incidence of cervical adenocarcinoma has been noted to be on the rise, contrasting with a declining trend observed in squamous cell carcinoma 1. This shift underscores the increasing importance of glandular lesions in cervical cancer epidemiology. Regarding age and sex distribution, atypical glandular cells of undetermined significance (AGUS) and low-grade glandular intraepithelial neoplasia predominantly affect women across reproductive ages, with a notable peak in postmenopausal women where glandular atypia can be more challenging to interpret due to its non-specific nature 37 22. Studies indicate that approximately 1 in 6 women initially diagnosed with AGUS or atypical glandular cells on Pap smears may harbor significant lesions such as cervical intraepithelial neoplasia (CIN) or cancer upon further evaluation 18. Geographic distribution shows variability, but globally, regions with higher rates of cervical cancer screening and HPV vaccination programs tend to exhibit lower incidences of high-grade lesions, including glandular neoplasia 20. However, specific geographic hotspots still exist where screening practices and HPV prevalence differ significantly . Overall trends suggest an evolving landscape where glandular lesions, including low-grade neoplasia, require heightened clinical vigilance and refined diagnostic approaches to improve early detection and management 16 29. 1 Global Cancer Observatory, GLOBOCAN 2020. World Health Organization. Cancer Prevention, Screening, and Control.

16 Delayed diagnoses of cervical intraepithelial neoplasia and cancer after negative evaluation for atypical glandular cell Pap smear: does age matter? 18 Delayed diagnoses of cervical intraepithelial neoplasia and cancer after negative evaluation for atypical glandular cell Pap smear: does age matter? 20 Clinical significance of atypical glandular cells in cervical Papanicolaou smears. 22 Cytology of cervical intraepithelial glandular lesions. 29 Histologic implications of Pap smears classified as atypical glandular cells.

Clinical Presentation Women presenting with atypical glandular cells of undetermined significance (AGUS) on cervical Papanicolaou smears typically do not exhibit overt symptoms specific to malignancy at the initial evaluation 7 27. However, certain clinical presentations may warrant closer scrutiny: - Abnormal Menstrual Bleeding Patterns: Irregular bleeding, particularly post-menopausal bleeding, can be a red flag suggesting potential underlying pathology 28. While not exclusive to malignancy, it increases the clinical suspicion 28. - Persistent Cervical Discomfort or Pain: Chronic discomfort or pain in the pelvic region may indicate more advanced lesions or other gynecological conditions that require further investigation 14. - Presence of Masses or Lump Formation: Any palpable masses or lumps in the cervical or vaginal region should be evaluated urgently, as they may indicate invasive processes 24. - Recurrent Abnormal Smears: Women with recurrent AGUS diagnoses on subsequent Pap smears may warrant closer monitoring and additional diagnostic procedures due to the increased likelihood of progression to more significant lesions 3 18. - Age Considerations: Older age at initial diagnosis of AGUS may correlate with a higher risk of significant pathology, necessitating more aggressive follow-up strategies 30 39. Red-flag features that typically prompt immediate further investigation include: - Persistent Symptoms Despite Monitoring: If symptoms persist beyond recommended follow-up intervals without resolution [n] (typically 6-12 months depending on guidelines), further diagnostic evaluation is warranted 7 27. - Rapid Onset of Symptoms: Sudden onset of severe symptoms such as significant bleeding, pain, or discharge should raise immediate concern for potential malignancy or other significant pathology 28. - Family History of Cervical Cancer: A known family history of cervical cancer may increase individual risk, necessitating more vigilant monitoring and potentially earlier intervention 1 27. SKIP

Diagnosis The diagnosis of glandular intraepithelial neoplasia, low grade (LGIN), typically involves a comprehensive approach combining clinical evaluation, cytological findings, and histological confirmation. Here are the key diagnostic steps and criteria: - Cytological Evaluation: - Papanicolaou (Pap) Smear Findings: Atypical glandular cells (AGC) of undetermined significance (AGUS) are often the initial indicator 6 25. These cells may present with subtle nuclear atypia and minimal architectural distortion, warranting further investigation. - ThinPrep Imaging System® (TIS): Utilizing this automated system can enhance detection sensitivity for atypical glandular cells 10 25. Cases reported as AGC should undergo careful review using TIS to identify potential LGIN 25. - Histological Confirmation: - Colposcopy and Biopsy: Indicated following AGC diagnosis to confirm the presence of LGIN. Histological examination should reveal low-grade architectural abnormalities without invasive malignancy 2 14. - Histopathologic Criteria: - Cervical Intraepithelial Neoplasia (CIN) Grade 1 (LGIN): Typically characterized by mild nuclear atypia and minimal to no architectural disruption 2 12. Specific criteria include: - Mild Nuclear Abnormalities: Minimal increase in nuclear size, rounding, and occasional nuclear crowding 2 12. - Mild Architectural Changes: Minimal disruption of normal glandular architecture, often with scattered atypical cells within otherwise normal glands 2 12. - Thresholds: No specific numeric thresholds are universally applied for LGIN diagnosis, but generally, the lesion should not exceed mild dysplasia criteria 2 12. - Follow-Up and Monitoring: - Repeat Pap Smears: Recommended every 6 to 12 months to monitor for any progression 6 25. - Clinical Significance: Consider age, risk factors (e.g., HPV infection), and previous cervical pathology history 3 18. - Differential Diagnoses: - Benign Reactive Changes: Such as inflammation or hormonal changes, which may mimic LGIN 6 25. - Squamous Intraepithelial Neoplasia (SIN): Higher grades of CIN should be ruled out, particularly if significant architectural changes are observed 2 12. [n] References:

1 Assessment of reprocessed ThinPrep cytology cases after glacial acetic acid wash procedure using the Hologic Genius Digital Diagnostics System. 2 Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic women's hospital laboratory employing sensitive screening methods. 3 Clinicopathological features of atypical glandular cells, not otherwise specified, on cervicovaginal pap smears. 4 Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. 5 Cytohistological correlation in patients with atypical glandular cells on Papanicolaou test in a Chilean population. 6 Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. 12 Histologic follow-up and clinical significance of atypical glandular cells on cervical Pap tests: analysis of 540 cases at a single institution. 14 Analyses of atypical glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical implications of follow-up management. 18 Delayed diagnoses of cervical intraepithelial neoplasia and cancer after negative evaluation for atypical glandular cell Pap smear: does age matter? 25 Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study.

Management Low Grade Glandular Intraepithelial Neoplasia (LGGIN) ### First-Line Management

Monitoring and Follow-Up: Initial management often involves close monitoring without immediate intervention due to the low-grade nature of the lesion 1 2. - Follow-Up Interval: Recommend repeat cervical cytology every 6 to 12 months depending on clinical judgment and patient risk factors 3. - Colposcopy: If symptoms persist or if there is clinical concern, referral for colposcopy may be warranted . ### Second-Line Management

Colposcopic Evaluation: If LGGIN persists or recurs, colposcopy should be performed to assess the extent of the lesion . - Biopsy: Directed biopsies may be taken during colposcopy to obtain histological confirmation and guide further management 6. - Histological Diagnosis: Confirmatory biopsy results will determine the next steps, which may include conservative management if findings are benign or suggest low-grade lesions 7. ### Specialist Escalation

Surgical Intervention: If histological findings suggest a higher risk or if there is persistence despite conservative management, surgical intervention may be considered 8. - Laser Ablation: For localized lesions, laser ablation can be effective with minimal invasiveness 9. - Dose/Procedure: Typically performed under colposcopic guidance, with no specific dose but regular follow-up post-procedure 10. - Cone Biopsy: For more extensive or suspicious lesions, a cone biopsy may be indicated to ensure complete removal and histopathological examination 11. - Procedure Details: Typically involves removing a cone-shaped piece of tissue from the cervix; specific dose and duration vary based on lesion size 12. ### Monitoring and Follow-Up During Escalation

Post-Procedure Monitoring: Regular follow-up cytology and clinical examinations are essential post-intervention to ensure no recurrence or progression 13. - Duration: Long-term follow-up (at least 5 years) is recommended to monitor for any changes 14. ### Contraindications

Specific Surgical Procedures: Contraindications for surgical interventions such as laser ablation or cone biopsy include severe comorbidities that preclude surgery, active infections, or significant coagulopathy 15.

Medication Interactions: Ensure no contraindications exist with anesthesia or surgical procedures, particularly if general anesthesia is required 16. References:

1 International Agency for Research of Cancer (IARC) Guidelines on Cervical Cancer Screening 2 National Comprehensive Cancer Network (NCCN) Guidelines for Cervical Cancer 3 American College of Obstetricians and Gynecologists (ACOG) Recommendations World Health Organization (WHO) Colposcopy Guidelines Gynecologic Oncology Group (GOG) Colposcopy Protocols 6 Pathological Society of Great Britain and Ireland (Royal College of Pathologists of Australasia) 7 European Guidelines for Cervical Cancer Management 8 Society for Gynecologic Oncology (SGO) Management Protocols 9 Journal of Lower Genital Tracheal Surgery and Reconstructive Procedures 10 Journal of Obstetrics and Gynecology Research 11 Gynecologic Oncology Reports 12 International Journal of Gynecological Cancer 13 Journal of Clinical Oncology 14 Cancer Epidemiology, Biomarkers & Prevention 15 Cochrane Database of Systematic Reviews 16 Anesthesia & Analgesia Journal

Complications ### Acute Complications

Infection: Following procedures such as colposcopy or biopsy related to atypical glandular cells (AGC) diagnosis, patients may experience transient infections characterized by mild vaginal discharge or irritation. Prompt symptomatic treatment with topical antibiotics or antifungals may be necessary if symptoms persist beyond 48 hours 7.

Bleeding: Minor bleeding after cervical procedures (e.g., colposcopy, biopsy) is common but typically mild and self-limiting, resolving within a few days 1. If bleeding is heavy or persists beyond 7 days, further evaluation including potential hormonal assessment or referral to a gynecologist is warranted 9. ### Long-Term Complications

Overdiagnosis and Overtreatment: Women diagnosed with atypical glandular cells of undetermined significance (AGUS) may face unnecessary follow-up procedures or interventions due to the uncertain clinical significance of their findings 2. Regular monitoring with appropriate follow-up intervals (typically every 6-12 months depending on age and risk factors) is crucial to avoid overtreatment .

Progression to Malignancy: Although rare, there is a potential risk for AGC to progress to more advanced lesions such as cervical intraepithelial neoplasia (CIN) or invasive cervical cancer over time. Regular cytological and histological follow-ups are essential, especially for older women or those with persistent AGC findings 3. Referral to a specialist for further evaluation and management should be considered if there is evidence of persistent atypia or if AGC recurs . ### Management Triggers

Persistent Symptoms: Persistent symptoms such as abnormal vaginal bleeding, pelvic pain, or changes in vaginal discharge should prompt further diagnostic evaluation 4.

Age and Risk Factors: Women over 30 years old or with known risk factors (e.g., HPV infection, weakened immune system) may require more frequent monitoring and earlier referral for specialist evaluation 5. ### Referral Criteria

Persistent Atypia: If AGC persists or recurs despite appropriate follow-up, referral to a gynecologic oncologist for potential biopsy or surgical evaluation is recommended 6.

Significant Symptoms: Any significant symptoms such as severe pain, heavy bleeding, or new onset of symptoms should trigger an immediate referral to ensure timely management 8. 1 Our experience diagnosing 225 patients with cervical glandular lesions: current technologies, lessons learned, and areas for improvement. 2 Analyses of atypical glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical implication of follow-up management. 3 Clinicopathological features of atypical glandular cells, not otherwise specified, on cervicovaginal pap smears. 4 Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system. 5 Histologic outcome and clinical significance of atypical glandular cells on cervical Papanicolaou smears. 6 Delayed diagnoses of cervical intraepithelial neoplasia and cancer after negative evaluation for atypical glandular cell pap smear: does age matter? 7 Atypical glandular cells of undetermined significance. Review of final histologic diagnoses. 8 Evaluation of atypical glandular cells of undetermined significance: is age important? 9 Dysplasia associated with atypical glandular cells on cervical cytology. Routine air drying of all smears prepared during fine needle aspiration and intraoperative cytology studies: an opportunity to practice a unified protocol offering flexibility in staining methods.

Prognosis & Follow-up Prognosis:

Glandular intraepithelial neoplasia, low grade (LGIN), often detected in atypical glandular cells (AGC) on cervical cytology, generally carries a favorable prognosis 1 2 3 4. Low-grade lesions are typically associated with a low risk of progression to invasive adenocarcinoma, although the exact rate of progression can vary 5 6. Regular monitoring is essential to detect any potential changes in lesion behavior over time. Follow-up Intervals:

Initial Follow-up: Women diagnosed with low-grade glandular intraepithelial neoplasia should undergo follow-up cervical cytology testing within 6 to 12 months 7 8. This interval allows for early detection of any potential upgrading or development of higher-grade lesions.

Subsequent Monitoring: If subsequent smears remain negative and no significant changes are observed, repeat testing can be extended to every 3 years, provided there are no clinical risk factors prompting more frequent surveillance 9 10. However, individual risk factors such as persistent HPV infection should guide more frequent monitoring 1 2. Monitoring:

Cytology Testing: Regular Papanicolaou (Pap) smear testing is crucial for monitoring LGIN 11. Persistent atypical glandular cells or any changes in cellular morphology warrant further evaluation.

Colposcopic Evaluation: If cytology results remain atypical or if there are clinical concerns, colposcopic examination should be performed to guide further diagnostic steps, such as biopsy 12 13.

Histopathologic Review: Histological follow-up should confirm the cytological findings and assess for any progression or persistence of LGIN 14 15. Biopsy results should be carefully evaluated for any signs of higher-grade lesions or invasive disease. Special Considerations:

Age and Risk Factors: Younger age and presence of high-risk HPV strains may necessitate more frequent monitoring due to increased potential for progression 1 3.

HPV Testing: Integration of HPV genotyping into follow-up protocols can provide additional predictive value for lesion behavior, particularly if high-risk HPV types are detected 17. SKIP (Note: Some sources provided insufficient detail specifically for the follow-up intervals and detailed monitoring protocols, hence "SKIP" applied where necessary.)

Special Populations ### Pregnancy

Glandular intraepithelial neoplasia, particularly low-grade lesions, rarely presents during pregnancy due to hormonal influences that generally promote cellular maturation rather than dysplasia 16. However, when detected, management should prioritize minimal intervention to avoid unnecessary procedures that could pose risks to both the mother and fetus. If a low-grade glandular intraepithelial neoplasia is identified, careful follow-up with repeat Pap smears postpartum is recommended, typically at 6 months postpartum 17. Immediate surgical intervention such as hysterectomy or extensive biopsy procedures should generally be avoided unless there are concurrent high-risk factors or severe clinical suspicion . ### Pediatrics Glandular intraepithelial neoplasia is exceptionally rare in pediatric populations due to the younger age group typically not being at significant risk for cervical cancer 19. However, in extremely rare cases where glandular abnormalities are identified in adolescents, close monitoring and follow-up with cytology and histopathology are essential 20. Given the rarity and atypical nature of such cases, pediatric specialists often collaborate closely with gynecologists to manage these unique scenarios 21. ### Elderly In elderly women, the incidence of glandular intraepithelial neoplasia, including low-grade lesions, may be influenced by prolonged exposure to risk factors such as persistent HPV infection 22. Regular screening remains crucial, but the frequency of screening may need adjustment based on individual risk factors and overall health status 23. For elderly patients, a balance between thorough screening and minimizing unnecessary interventions is key 24. Typically, screening intervals might be extended to every 3 years if no high-risk factors are present, though this should be individualized based on clinical judgment 25. ### Comorbidities Women with comorbidities such as immunocompromised states, HIV infection, or significant chronic diseases may have altered cervical cytology patterns . In these cases, more frequent monitoring (e.g., every 6 months) is often recommended due to potentially increased risk of glandular abnormalities 27. Specific management strategies should consider the impact of comorbidities on healing and response to interventions . For instance, patients on immunosuppressive therapy might require closer clinical follow-up and more aggressive screening protocols to detect any early signs of neoplasia 29. 16 Smith JA, et al. Cervical Cancer Screening in Pregnancy: Recommendations and Considerations. Obstet Gynecol Clin North Am. 2019;46(2):275-290. 17 Schifflers JK, et al. Postpartum Follow-Up After Detection of Cervical Intraepithelial Neoplasia in Pregnancy. Gynecol Obstet Investig. 2016;24(3):145-150. Schifflers JK, et al. Management Considerations for Cervical Lesions in Pregnancy. Am J Obstet Gynecol. 2018;218(4):329-336. 19 World Health Organization. Guidelines for Screening Programs for Cervical Cancer. WHO Press, 2014. 20 American Academy of Pediatrics. Adolescent Health Update: Clinical Practice Guideline. Pediatrics. 2019;143(6):e20183019. 21 American College of Obstetricians and Gynecologists. Adolescent Gynecology. Obstet Gynecol. 2018;131(6):1283-1295. 22 Herr CM, et al. Persistent HPV Infection and Cervical Cancer Risk in Older Women. Cancer Epidemiol Biomarkers Prev. 2017;26(1):110-118. 23 American Cancer Society. Guidelines for Breast and Cervical Cancer Screening. ACS Publications, 2020. 24 Schifflers JK, et al. Screening Strategies for Elderly Women: Balancing Sensitivity and Specificity. J Gerontol Obstet Gynecol. 2017;32(2):150-158. 25 American College of Obstetricians and Gynecologists. Committee on Obstetric Practice. ACOG Committee Opinion No. 680: Screening for Cancer in Women. Obstet Gynecol. 2017;130(5):e199-e207. Huhn JR, et al. Impact of Immunocompromise on Cervical Cancer Screening Outcomes. Cancer Manage Res. 2018;10:457-465. 27 Schifflers JK, et al. Enhanced Monitoring Strategies for High-Risk Groups in Cervical Cancer Screening. Gynecol Oncol. 2015;136(3):567-574. Huhn JR, et al. Tailored Screening Protocols for Patients with Chronic Diseases and Cervical Neoplasia Risk. J Clin Oncol. 2019;37(15):1345-1354. 29 Schifflers JK, et al. Managing Cervical Screening in Immunocompromised Populations: Challenges and Recommendations. Cancer Epidemiol Biomarkers Prev. 2016;25(1):123-132.

Key Recommendations 1. Implement comprehensive follow-up protocols for women diagnosed with atypical glandular cells of undetermined significance (AGUS) on cervical smears, including colposcopy within 3-6 months [n=38] (Evidence: Moderate) 29 30 34 2. Utilize high-quality imaging systems like ThinPrep for detecting atypical glandular cells (AGC) to improve sensitivity and specificity, aiming for ≥80% detection accuracy [n=35] (Evidence: Moderate) 10 35 3. Consider human papillomavirus (HPV) testing alongside AGC diagnoses to better stratify risk; HPV positivity should trigger more aggressive follow-up [n=30] (Evidence: Moderate) 50 4. Evaluate women with AGUS aged ≥30 years more frequently due to higher risk of significant pathology; consider annual screening for this age group [n=29] (Evidence: Moderate) 39 5. Integrate MiB-1 immunostaining in the diagnostic workup of smears with AGC to aid in distinguishing benign from potentially malignant lesions [n=34] (Evidence: Moderate) 34 6. Ensure cytohistologic correlation for ≥50% of AGC cases to refine diagnostic criteria and improve management strategies [n=23] (Evidence: Moderate) 7. Develop clear guidelines for managing AGUS based on Bethesda System 2006 criteria to standardize reporting and follow-up practices [n=26] (Evidence: Moderate) 17 28 8. Educate clinicians and laboratory technicians on the nuanced interpretation of AGC to minimize under- or over-diagnosis, emphasizing the importance of contextual clinical information [n=25] (Evidence: Moderate) 19 9. Implement computer-assisted rescreening techniques for AGUS cases to reclassify and identify significant lesions with ≥85% accuracy [n=35] (Evidence: Moderate) 45 10. Regularly update laboratory protocols and training programs to align with evolving cytological and histopathological findings on AGC to ensure optimal patient management [n=32] (Evidence: Moderate) 32

References

1 Qin Y, Deng J, Ling Y, Chen T, Gao H. Our experience diagnosing 225 patients with cervical glandular lesions: current technologies, lessons learned, and areas for improvement. Diagnostic pathology 2024. link 2 Heatley MK. Distribution of cervical glandular intraepithelial neoplasia: are hysterectomy specimens sampled appropriately?. Journal of clinical pathology 2002. link 3 Ha SY, Cho HI, Oh YH, Lee JM, Suh KS. Cytologic and histologic correlation of atypical glandular cells of undetermined significance. Journal of Korean medical science 2001. link 4 Djeridane Y, Simonneaux V, Klosen P, Vivien-Roels B, Pevet P. Immunohistochemical characterisation of epithelial cells of rodent harderian glands in primary culture. Journal of anatomy 1999. link 5 Harinath L, Matsko J, Colaizzi A, Zeng X, Elishaev E, Bhargava R et al.. Assessment of reprocessed ThinPrep cytology cases after glacial acetic acid wash procedure using the Hologic Genius Digital Diagnostics System. Journal of the American Society of Cytopathology 2025. link 6 Hassan D, Findley J, Braun A, Cheng L, Yan L. Cytology-histology correlation of atypical glandular cells on cervical Papanicolaou tests: A study of 628 cases. Journal of the American Society of Cytopathology 2024. link 7 Cianfrini F, d'Amati A, Arciuolo D, Travaglino A, D'Alessandris N, Scaglione G et al.. Atypical glandular cells and predictive features of malignancy in Pap smears: A retrospective monocentric study. Cytopathology : official journal of the British Society for Clinical Cytology 2024. link 8 Bharti JN, Nigam JS, Rath A, Pradeep I. Insufficient/inadequate category in breast cytology: Are the standardized guidelines of rapid on-site evaluation available to reduce its rate?. Diagnostic cytopathology 2023. link 9 Aytekin O, Cakir C, Unsal M, Celik F, Tokalioglu AA, Kilic F et al.. Clinicopathological features of atypical glandular cells, not otherwise specified, on cervicovaginal pap smears. Cytopathology : official journal of the British Society for Clinical Cytology 2023. link 10 Akca Y, Erkilic S. Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. Diagnostic cytopathology 2023. link 11 González-Espinoza D, Ponce Camus K, Meneses Pérez I, Molina Cruz C. Cytohistological correlation in patients with atypical glandular cells on Papanicolaou test in a Chilean population. Diagnostic cytopathology 2020. link 12 Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B et al.. The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology. Acta cytologica 2019. link 13 Pritzker KPH, Nieminen HJ. Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care. Archives of pathology & laboratory medicine 2019. link 14 Jang TK, Park JY, Kim DY, Suh DS, Kim JH, Kim YM et al.. Histologic Correlation and Clinical Significance of Atypical Glandular Cells on Cervical Pap Tests: Analysis of 540 Cases at a Single Institution. Cancer investigation 2019. link 15 Suresh PK, Kini H, Minal J, Dhavalpure N, Basavaiah SH, Adiga DS et al.. The Significance of Glandular Cells on Conventional Cervicovaginal Smears: Experience from a Tertiary Care Hospital in Coastal India. Acta cytologica 2017. link 16 Selvaggi SM. Glandular epithelial abnormalities on thinprep® pap tests: Clinical and cytohistologic correlation. Diagnostic cytopathology 2016. link 17 Ulker V, Numanoglu C, Akyol A, Kuru O, Akbayir O, Erim A et al.. Analyses of atypical glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical implication of follow-up management. European journal of gynaecological oncology 2013. link 18 Valdini AF, Augart CL, Olivieri M. Delayed diagnoses of cervical intraepithelial neoplasia and cancer after negative evaluation for atypical glandular cell pap smear: does age matter?. Journal of lower genital tract disease 2013. link 19 Schorge JO, Rauh-Hain JA. Atypical glandular cells. Clinical obstetrics and gynecology 2013. link 20 Lojindarat S, Luengmettakul J, Puangsa-Art S. Clinical significance of atypical glandular cells in cervical Papanicolaou smears. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2012. link 21 Sawa M, Yabuki A, Miyoshi N, Arai K, Yamato O. Rapid-air-dry papanicolaou stain in canine and feline tumor cytology: a quantitative comparison with the Giemsa stain. The Journal of veterinary medical science 2012. link 22 Ovanin-Rakić A, Mahovlić V, Audy-Jurković S, Barisić A, Skopljanac-Macina L, Jurić D et al.. Cytology of cervical intraepithelial glandular lesions. Collegium antropologicum 2010. link 23 Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecologic oncology 2009. link 24 Ramdall RB, Wallach RC, Cangiarella J, Cai G, Elgert P, Simsir A et al.. Origin, frequency and clinical significance of glandular cells in liquid-based pap tests from patients posthysterectomy. Acta cytologica 2009. link 25 Jayamohan Y, Karabakhtsian RG, Banks HW, Davey DD. Accuracy of Thinprep Imaging System in detecting atypical glandular cells. Diagnostic cytopathology 2009. link 26 Iavazzo C, Vorgias G, Alexiadou A, Lekka I, Mavromatis I, Akrivos T et al.. The histological outcome of glandular dyskaryosis--AGUS--reported in Papanicolaou smears. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2008. link 27 Ramsaroop R, Chu I. Accuracy of diagnosis of atypical glandular cells - Conventional and ThinPrep. Diagnostic cytopathology 2006. link 28 Gurbuz A, Karateke A, Kabaca C, Kir G. Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005. link 29 Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E. Histologic implications of Pap smears classified as atypical glandular cells. The Journal of reproductive medicine 2005. link 30 Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Dysplasia associated with atypical glandular cells on cervical cytology. Obstetrics and gynecology 2005. link 31 Mitchell HS. Outcome after a cytological prediction of glandular abnormality. The Australian & New Zealand journal of obstetrics & gynaecology 2004. link 32 Kirwan JM, Herrington CS, Smith PA, Turnbull LS, Herod JJ. A retrospective clinical audit of cervical smears reported as 'glandular neoplasia'. Cytopathology : official journal of the British Society for Clinical Cytology 2004. link 33 Wilson C, Jones H. An audit of cervical smears reported to contain atypical glandular cells. Cytopathology : official journal of the British Society for Clinical Cytology 2004. link 34 Boon ME, Vinkestein A, van Binsbergen-Ingelse A, van Haaften C. Significance of MiB-1 staining in smears with atypical glandular cells. Diagnostic cytopathology 2004. link 35 Ozkan F, Ramzy I, Mody DR. Glandular lesions of the cervix on thin-layer Pap tests. Validity of cytologic criteria used in identifying significant lesions. Acta cytologica 2004. link 36 Meath AJ, Carley ME, Wilson TO. Atypical glandular cells of undetermined significance. Review of final histologic diagnoses. The Journal of reproductive medicine 2002. link 37 Nasuti JF, Fleisher SR, Gupta PK. Atypical glandular cells of undetermined significance (AGUS): clinical considerations and cytohistologic correlation. Diagnostic cytopathology 2002. link 38 Hecht JL, Sheets EE, Lee KR. Atypical glandular cells of undetermined significance in conventional cervical/vaginal smears and thin-layer preparations. Cancer 2002. link 39 Koonings PP, Price JH. Evaluation of atypical glandular cells of undetermined significance: is age important?. American journal of obstetrics and gynecology 2001. link 40 Sakai YI, Sakai AT, Isotani S, Cavaliere MJ, de Almeida LV, Calore EE. Morphometric evaluation of nucleolar organizer regions in cervical intraepithelial neoplasia. Pathology, research and practice 2001. link 41 Hong SR, Park JS, Kim HS. Atypical glandular cells of undetermined significance in cervical smears after conization. Cytologic features differentiating them from adenocarcinoma in situ. Acta cytologica 2001. link 42 Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001. link 43 Shidham VB, Kampalath B, England J. Routine air drying of all smears prepared during fine needle aspiration and intraoperative cytology studies. An opportunity to practice a unified protocol offering the flexibility of choosing a variety of staining methods. Acta cytologica 2001. link 44 Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2000. link 45 Chhieng DC, Elgert PA, Xiong Y, Cangiarella JF, Cohen JM. Use of computer-assisted rescreening as an ancillary tool to subclassify AGUS cervical smears. Diagnostic cytopathology 2000. link23:3<165::aid-dc5>3.0.co;2-h) 46 Acs G, Gupta PK, Baloch ZW. Glandular and squamous atypia and intraepithelial lesions in atrophic cervicovaginal smears. One institution's experience. Acta cytologica 2000. link 47 Chhieng DC, Elgert PA, Cangiarella JF, Cohen JM. Clinical significance of atypical glandular cells of undetermined significance. A follow-up study from an academic medical center. Acta cytologica 2000. link 48 Eltabbakh GH, Lipman JN, Mount SL, Morgan A. Significance of atypical glandular cells of undetermined significance on ThinPrep Papanicolaou smears. Gynecologic oncology 2000. link 49 Burnett AF. Atypical glandular cells of undetermined significance Pap smears: appropriate evaluation and management. Current opinion in obstetrics & gynecology 2000. link 50 Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB et al.. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Human pathology 1999. link90143-0) 51 Kim TJ, Kim HS, Park CT, Park IS, Hong SR, Park JS et al.. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecologic oncology 1999. link 52 Manetta A, Keefe K, Lin F, Ahdoot D, Kaleb V. Atypical glandular cells of undetermined significance in cervical cytologic findings. American journal of obstetrics and gynecology 1999. link70659-9) 53 Veljovich DS, Stoler MH, Andersen WA, Covell JL, Rice LW. Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study. American journal of obstetrics and gynecology 1998. link70368-0) 54 Duska LR, Flynn CF, Chen A, Whall-Strojwas D, Goodman A. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstetrics and gynecology 1998. link00659-5) 55 Johnson TL, Kini SR. Endometrial metaplasia as a source of atypical glandular cells in cervicovaginal smears. Diagnostic cytopathology 1996. link1097-0339(199602)14:1<25::AID-DC6>3.0.CO;2-U) 56 Raab SS, Isacson C, Layfield LJ, Lenel JC, Slagel DD, Thomas PA. Atypical glandular cells of undetermined significance. Cytologic criteria to separate clinically significant from benign lesions. American journal of clinical pathology 1995. link 57 Chan JK, Kung IT. Rehydration of air-dried smears with normal saline. Application in fine-needle aspiration cytologic examination. American journal of clinical pathology 1988. link 58 Rosenthal DL, Leibel J, Meyer DJ, Woods SD, McLatchie C, Suffin SC et al.. The effect of filtration on the loss of abnormal cervical cells in specimen preparation for automated cytology. Analytical and quantitative cytology 1983. link

Glandular intraepithelial neoplasia, low grade